Management of significant pleural effusion at ovarian cancer diagnosis: Outcomes of triage to neoadjuvant chemotherapy without thoracic assessment
Limited evidence directs the best management for patients presenting with clinical Stage IVA disease. Our data represent a particularly high-risk subgroup which may be characteristic of patients with large pleural effusions and adds important information showing that approximately half of these patients have ≥2 indications to favor NACT, signifying their high-risk status. Despite this, when CGR in the abdomen was achieved at IDS, median OS was greater than 5 years.
Authors
- Conway Xu
- Matthew Stephen Block (ORCID: https://orcid.org/0000-0001-5692-4219)
- Carrie Langstraat (ORCID: https://orcid.org/0000-0001-9361-8392)
- Kelly H. Bruce (ORCID: https://orcid.org/0000-0002-6943-9770)
- Chiara Ainio
- Stuart A. Ostby (ORCID: https://orcid.org/0000-0002-3524-8626)
- William A. Cliby (ORCID: https://orcid.org/0000-0002-7565-9884)
- Amanika Kumar (ORCID: https://orcid.org/0000-0002-1470-1305)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1016/j.gore.2025.101944
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00